

PATIENT NAME : SMIT CHANDARANA	REF. DOCTOR :	SELF
CODE/NAME & ADDRESS : C000138364 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	ACCESSION NO : 0321WK000908 PATIENT ID : SMITM021292321	AGE/SEX : 30 Years Male
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156		RECEIVED : 25/11/2023 09:37:22 REPORTED :27/11/2023 16:15:10
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units

MEDI WHEEL FULL BODY HEALTH CHECK UP B	ELOW 40 MALE	
XRAY-CHEST		
IMPRESSION	NO ABNORMALITY DETECTED	
ECG		
ECG	NORMAL SINUS RHYTHM	
MEDICAL HISTORY		
RELEVANT PRESENT HISTORY	NOT SIGNIFICANT	
RELEVANT PAST HISTORY	NOT SIGNIFICANT	
RELEVANT PERSONAL HISTORY	NOT SIGNIFICANT	
RELEVANT FAMILY HISTORY	DIABETES	
OCCUPATIONAL HISTORY	NOT SIGNIFICANT	
HISTORY OF MEDICATIONS	NOT SIGNIFICANT	
ANTHROPOMETRIC DATA & BMI		
HEIGHT IN METERS	1.83	mts
WEIGHT IN KGS.	112.1	Kgs
ВМІ	33	BMI & Weight Status as followg/sqmts Below 18.5: Underweight 18.5 - 24.9: Normal 25.0 - 29.9: Overweight 30.0 and Above: Obese
GENERAL EXAMINATION		
MENTAL / EMOTIONAL STATE	NORMAL	
PHYSICAL ATTITUDE	NORMAL	
GENERAL APPEARANCE / NUTRITIONAL STATUS	OBESE	
BUILT / SKELETAL FRAMEWORK	TALL STATURE	
FACIAL APPEARANCE	NORMAL	
SKIN	NORMAL	
UPPER LIMB	NORMAL	
LOWER LIMB	NORMAL	
NECK	NORMAL	
NECK LYMPHATICS / SALIVARY GLANDS	NOT ENLARGED OR TEND	ER
THYROID GLAND	NOT ENLARGED	
TEMPERATURE	NORMAL	

P. V. Kipudia

Dr.Priyank Kapadia Physician







View Report





PATIENT NAME : SMIT CHANDARANA	REF. DOCTOR : SELF		
CODE/NAME & ADDRESS : C000138364	ACCESSION NO : 0321WK000908	AGE/SEX : 30 Years Male	
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	PATIENT ID : SMITM021292321	DRAWN :	
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 25/11/2023 09:37:22	
NEW DELHI 110030	ABHA NO :	REPORTED :27/11/2023 16:15:10	
8800465156			
Test Report Status <u>Final</u>	Results Biologica	Reference Interval Units	
PULSE	86/MIN		
RESPIRATORY RATE	NORMAL		
CARDIOVASCULAR SYSTEM			
BP	122/84 MM HG	mm/Hg	
	(SITTING)		
PERICARDIUM	NORMAL		
APEX BEAT	NORMAL		
HEART SOUNDS	S1, S2 HEARD NORMALLY		
MURMURS	ABSENT		
RESPIRATORY SYSTEM			
SIZE AND SHAPE OF CHEST	NORMAL		
MOVEMENTS OF CHEST	SYMMETRICAL		
BREATH SOUNDS INTENSITY	NORMAL		
BREATH SOUNDS QUALITY	VESICULAR (NORMAL)		
ADDED SOUNDS	ABSENT		
APPEARANCE	NORMAL		
LIVER			
SPLEEN	NOT PALPABLE		
	NORMAL		
HIGHER FUNCTIONS	NORMAL		
CRANIAL NERVES	NORMAL		
CEREBELLAR FUNCTIONS	NORMAL		
SENSORY SYSTEM	NORMAL		
MOTOR SYSTEM	NORMAL		
	NORMAL		
	NORMAL		
SPINE	NORMAL		
JOINTS BASIC EVE EXAMINATION	NORMAL		
BASIC EYE EXAMINATION	WITH GLASSES NORMAL		
DISTANT VISION LEET EVE WITH CLASSES	WITH GLASSES NORMAL		
DISTANT VISION LEFT EYE WITH GLASSES	WITH GLASSES NORMAL		
NEAR VISION RIGHT EYE WITHOUT GLASSES			

P. V. Equilia

Dr.Priyank Kapadia Physician Page 2 Of 19









PATIENT NAME : SMIT CHANDARANA	REF. DOCTOR :	SELF
CODE/NAME & ADDRESS : C000138364 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0321WK000908 PATIENT ID : SMITM021292321 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :30 Years Male DRAWN : RECEIVED :25/11/2023 09:37:22 REPORTED :27/11/2023 16:15:10
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units
NEAR VISION LEFT EYE WITHOUT GLASSES COLOUR VISION SUMMARY	WITHIN NORMAL LIMIT NORMAL	

NOT SIGNIFICANT

FBS:- HIGH, PPBS:- HIGH

RELEVANT HISTORY RELEVANT GP EXAMINATION FINDINGS RELEVANT LAB INVESTIGATIONS

RELEVANT NON PATHOLOGY DIAGNOSTICS REMARKS / RECOMMENDATIONS HDL:- LOW USG ABDOMEN:- FATTY LIVER WITH HEPETOMEGALY FBS:- HIGH, PPBS:- HIGH

ADV:- REDUCE INTAKE OF SWEET, SUGAR, STARCH IN DIET, REGULAR PHYSICAL EXERCISE, REPEAT FBS, PPBS AND HBA1C AND DIABETOLOGIST OPINION

Comments

OUR PANEL DOCTORS FOR NON-PATHOLOGY TESTS:-

CHECK UP DONE BY:- DR. NAMRATA AGRAWAL (M.B.B.S)

REPORT REVIEWED BY:- DR. PRIYANK KAPADIYA (M.B.B.S DNB MEDICINE)

RADIOLOGIST:- DR. SAHIL N SHAH (M.D.RADIOLOGY)

P. V. Kipudia

Dr.Priyank Kapadia Physician

PERFORMED AT : Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India Tel : 079-48912999,079-48913999,079-48914999 Email : customercare.ahmedabad@agilus.in Page 3 Of 19









PATIENT NAME : SMIT CHANDARANA	REF. DOCTOR : S	SELF
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	PATIENT ID : SMITM021292321 CLIENT PATIENT ID:	AGE/SEX :30 Years Male DRAWN : RECEIVED :25/11/2023 09:37:22 REPORTED :27/11/2023 16:15:10
Test Report Status <u>Final</u>	Results	Units

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE ULTRASOUND ABDOMEN ULTRASOUND ABDOMEN FATTY LIVER WITH HEPATOMEGALY TMT OR ECHO CLINICAL PROFILE 2D ECHO:-

1) NORMAL CHAMBERS AND VALVES.

2) GOOD LV SYSTOLIC FUNCTION. LVEF 60%. NO RWMA AT REST.

NO MR, AR, TR.

- NORMAL LV COMPLIANCE.
- 5) NO PAH.
- 6) NO LV CLOT, VEGETATION OR PERICARDIAL EFFUSION.
- IAS/IVS INTACT.

Interpretation(s) MEDICAL

HISTORY. HISTORY. THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOLABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.

P. V. Kepudia

Dr.Priyank Kapadia Physician

PERFORMED AT : Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India Tel : 079-48912999,079-48913999,079-48914999 Email : customercare.ahmedabad@agilus.in Page 4 Of 19





View Report



Test Report Status

<u>Final</u>



Biological Reference Interval Units

PATIENT NAME : SMIT CHANDARANA	REF. DOCTOR : S	SELF
CODE/NAME & ADDRESS : C000138364	ACCESSION NO : 0321WK000908	AGE/SEX : 30 Years Male
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	PATIENT ID : SMITM021292321	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 25/11/2023 09:37:22
NEW DELHI 110030	ABHA NO :	REPORTED :27/11/2023 16:15:10
8800465156		
		<u> </u>

Results

НА	EMATOLOGY - CBC		
MEDI WHEEL FULL BODY HEALTH CHECK UP BE	LOW 40 MALE		
BLOOD COUNTS, EDTA WHOLE BLOOD			
HEMOGLOBIN (HB) METHOD : PHOTOMETRIC MEASUREMENT	15.8	13.0 - 17.0	g/dL
RED BLOOD CELL (RBC) COUNT METHOD : COULTER PRINCIPLE	5.23	4.5 - 5.5	mil/µL
WHITE BLOOD CELL (WBC) COUNT METHOD : COULTER PRINCIPLE	7.13	4.0 - 10.0	thou/µL
PLATELET COUNT	278	150 - 410	thou/µL
METHOD : COULTER PRINCIPLE			
RBC AND PLATELET INDICES			
HEMATOCRIT (PCV)	46.0	40.0 - 50.0	%
	07.0	02.0 101.0	fL
MEAN CORPUSCULAR VOLUME (MCV) METHOD : DERIVED PARAMETER FROM RBC HISTOGRAM	87.9	83.0 - 101.0	IL.
MEAN CORPUSCULAR HEMOGLOBIN (MCH) METHOD : CALCULATED	30.3	27.0 - 32.0	pg
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD : CALCULATED	34.4	31.5 - 34.5	g/dL
RED CELL DISTRIBUTION WIDTH (RDW) METHOD : DERIVED PARAMETER FROM RBC HISTOGRAM	14.6 High	11.6 - 14.0	%
MENTZER INDEX	16.8		
METHOD : CALCULATED PARAMETER			
MEAN PLATELET VOLUME (MPV)	7.1	6.8 - 10.9	fL
METHOD : DERIVED PARAMETER FROM PLATELET HISTOGRAM			
			0/
NEUTROPHILS METHOD : OPTICAL IMPEDENCE & MICROCSOPY	58	40 - 80	%
LYMPHOCYTES	31	20 - 40	%
METHOD : OPTICAL IMPEDENCE & MICROCSOPY			
MONOCYTES METHOD : OPTICAL IMPEDENCE & MICROCSOPY	6	2.0 - 10.0	%
EOSINOPHILS	5	1.0 - 6.0	%

Dr.Miral Gajera Consultant Pathologist

Page 5 Of 19

View Report







PATIENT NAME : SMIT CHANDARANA		REF. DOCTOR : SELF		
CODE/NAME & ADDRESS : C000138364 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 032 PATIENT ID : SMI CLIENT PATIENT ID: ABHA NO :	TM021292321 DRAWN RECEIVED	:30 Years Male : :25/11/2023 09:37:22 :27/11/2023 16:15:10	
Test Report Status <u>Final</u>	Results	Biological Reference	e Interval Units	
METHOD : OPTICAL IMPEDENCE & MICROCSOPY BASOPHILS METHOD : IMPEDANCE	0	0 - 1	%	
ABSOLUTE NEUTROPHIL COUNT METHOD : CALCULATED	4.14	2.0 - 7.0	thou/µL	
ABSOLUTE LYMPHOCYTE COUNT METHOD : CALCULATED PARAMETER	2.21	1.0 - 3.0	thou/µL	
ABSOLUTE MONOCYTE COUNT METHOD : CALCULATED PARAMETER	0.43	0.2 - 1.0	thou/µL	
ABSOLUTE EOSINOPHIL COUNT METHOD : CALCULATED	0.36	0.02 - 0.50	thou/µL	
ABSOLUTE BASOPHIL COUNT METHOD : CALCULATED	0.00 Low	0.02 - 0.10	thou/µL	
NEUTROPHIL LYMPHOCYTE RATIO (NLR) METHOD : CALCULATED PARAMETER	1.9			
MORPHOLOGY				
RBC METHOD : MICROSCOPIC EXAMINATION	NORMOCYTIC NORM	IOCHROMIC		
WBC METHOD : MICROSCOPIC EXAMINATION	NORMAL MORPHOLO	DGY		
PLATELETS METHOD : MICROSCOPIC EXAMINATION	ADEQUATE			
REMARKS	NO PREMATURE CEL	LS ARE SEEN. MALARIAL PARA	ASITE NOT DETECTED.	

METHOD : MICROSCOPIC EXAMINATION

Interpretation(s) BLOOD COUNTS,EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology. RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13)

from Beta thalassaemia trait (<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.46.1% COVID-19 patients with mild disease mild become severe. By contrast, when age < 49.5 years old and NLR = 3.46.1% COVID

3.3, COVID-19 patients tend to show mild disease. (Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients A.-P. Yang, et al. International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.

Dr.Miral Gajera Consultant Pathologist

Page 6 Of 19





View Report

View Details

Patient Ref. No. 775000005547783



PATIENT NAME : SMIT CHANDARANA	REF. DOCTOR : SELF		
CODE/NAME & ADDRESS : C000138364	ACCESSION NO : 0321WK000908	AGE/SEX : 30 Years Male	
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	PATIENT ID : SMITM021292321	DRAWN :	
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 25/11/2023 09:37:22	
NEW DELHI 110030	ABHA NO :	REPORTED :27/11/2023 16:15:10	
8800465156			
(

Test Report	Status	Final
-------------	--------	--------------

Biological Reference Interval Units

[HAEMATOLOGY					
MEDI WHEEL FULL BODY HEALTH CHECK UP I						
ERYTHROCYTE SEDIMENTATION RATE (ESR), BLOOD	EDTA					
E.S.R METHOD : WESTERGREN METHOD	09	0 - 14	mm at 1 hr			
GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA BLOOD	GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD					
HBA1C	4.5	Non-diabetic: < 5.7 Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5 Therapeutic goals: < 7.0 Action suggested : > 8.0 (ADA Guideline 2021)	%			
METHOD : HPLC ESTIMATED AVERAGE GLUCOSE(EAG)	82.5	< 116.0	mg/dL			

Interpretation(s)

ERYTHROCYTE SEDIMENTATION RATE (ESR), EDTA BLOOD-**TEST DESCRIPTION** :-Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change. TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging. Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias,

Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis). In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum. **Decreased** in: Polycythermia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR : Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia False Decreased : Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs (Quinine,

salicylates)

REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis,10th edition. GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-**Used For**:

1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.

Diagnosing diabetes.
 Identifying patients at increased risk for diabetes (prediabetes).

Dr.Miral Gajera Consultant Pathologist





Page 7 Of 19

View Details





PATIENT NAME : SMIT CHANDARANA	REF. DOCTOR :	SELF
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	ACCESSION NO : 0321WK000908 PATIENT ID : SMITM021292321 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :30 Years Male DRAWN : RECEIVED :25/11/2023 09:37:22 REPORTED :27/11/2023 16:15:10
Test Report Status Final	Results Biological	Reference Interval Units

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range. 1. eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels. 2. eAG gives an evaluation of blood glucose levels for the last couple of months. 3. eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c - 46.7

HbA1c Estimation can get affected due to :

1. Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.

Z.Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.
 Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates

addiction are reported to interfere with some assay methods, falsely increasing results. 4. Interference of hemoglobinopathies in HbA1c estimation is seen in

a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)

c) HDF > 25% on alternate pattform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

Dr.Miral Gajera Consultant Pathologist

PERFORMED AT : Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India Tel : 079-48912999,079-48913999,079-48914999 Email : customercare.ahmedabad@agilus.in

Page 8 Of 19





View Report





PATIENT NAME : SMIT CHANDARANA	REF. DOCTOR : S	SELF
	ACCESSION NO : 0321WK000908	AGE/SEX : 30 Years Male
	PATIENT ID : SMITM021292321	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 25/11/2023 09:37:22
	ABHA NO :	REPORTED :27/11/2023 16:15:10
8800465156		

Test Report Status <u>Final</u> Results

Biological Reference Interval Units

IMMUNOHAEMATOLOGY MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE ABO GROUP & RH TYPE, EDTA WHOLE BLOOD ABO GROUP TYPE AB METHOD : TUBE AGGLUTINATION POSITIVE RH TYPE METHOD : TUBE AGGLUTINATION

Interpretation(s) ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.

Dr.Miral Gajera Consultant Pathologist



View Repor





PATIENT NAME : SMIT CHANDARANA	REF. DOCTOR :	SELF
		AGE/SEX : 30 Years Male
F-703, LADO SARAI, MEHRAULISOUTH WEST	511111021292521	DRAWN : RECEIVED : 25/11/2023 09:37:22
	ABHA NO :	REPORTED :27/11/2023 16:15:10

Test Repo	rt Status	<u>Final</u>

Biological Reference Interval Units

	BIOCHEMISTRY		
MEDI WHEEL FULL BODY HEALTH CHECK UP BE	LOW 40 MALE		
GLUCOSE FASTING, FLUORIDE PLASMA			
FBS (FASTING BLOOD SUGAR)	109 High	74 - 99	mg/dL
METHOD : HEXOKINASE			
GLUCOSE, POST-PRANDIAL, PLASMA			
PPBS(POST PRANDIAL BLOOD SUGAR) METHOD : HEXOKINASE	145 High	70 - 140	mg/dL
	150	Desirable: < 200	mg/dL
CHOLESTEROL, TOTAL	150	Desirable: < 200 BorderlineHigh: 200 - 239 High: > or = 240	ng/ac
METHOD : ENZYMATIC, COLORIMETRIC		-	
TRIGLYCERIDES	121	Desirable: < 150 BorderlineHigh: 150 - 199 High: 200 - 499 Very High: $>$ or $= 500$	mg/dL
METHOD : ENZYMATIC, COLORIMETRIC		-, 5	
HDL CHOLESTEROL	39 Low	< 40 Low > or = 60 High	mg/dL
CHOLESTEROL LDL	87	Adult levels: Optimal < 100 Near optimal/above optimal 100-129 Borderline high : 130-159 High : 160-189 Very high : = 190	mg/dL :
NON HDL CHOLESTEROL	111	Desirable: Less than 130 Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220	mg/dL
VERY LOW DENSITY LIPOPROTEIN	24.2	< or = 30	mg/dL
CHOL/HDL RATIO	3.9	3.3 - 4.4	
LDL/HDL RATIO	-1.6 Low	0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Modera Risk >6.0 High Risk	

Dr.Miral Gajera Consultant Pathologist

Page 10 Of 19







PATIENT NAME : SMIT CHANDARANA	REF. DOCTOR :	SELF
	ACCESSION NO : 0321WK000908 PATIENT ID : SMITM021292321	AGE/SEX : 30 Years Male
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID: ABHA NO :	RECEIVED : 25/11/2023 09:37:22 REPORTED : 27/11/2023 16:15:10
8800465156		
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units

Interpretation(s)

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

Risk Stratification for	ASCVD (Atherosclerotic cardiovascular dis	sease) by Lipid Association of India	
Risk Category			
Extreme risk group	A.CAD with > 1 feature of high risk group		
	B. CAD with > 1 feature of Very high risk g	roup or recurrent ACS (within 1 year) despite LDL-C < or =	
	50 mg/dl or polyvascular disease		
Very High Risk	1. Established ASCVD 2. Diabetes with 2 r	najor risk factors or evidence of end organ damage 3.	
	Familial Homozygous Hypercholesterolemia	a	
High Risk	1. Three major ASCVD risk factors. 2. Diabetes with 1 major risk factor or no evidence of end organ		
	damage. 3. CKD stage 3B or 4. 4. LDL >19	90 mg/dl 5. Extreme of a single risk factor. 6. Coronary	
	Artery Calcium - CAC >300 AU. 7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid plaque		
Moderate Risk	2 major ASCVD risk factors		
Low Risk	0-1 major ASCVD risk factors		
Major ASCVD (Ath	erosclerotic cardiovascular disease) Risk Fa	ictors	
1. Age > or = 45 year	1. Age > or = 45 years in males and > or = 55 years in females 3. Current Cigarette smoking or tobacco use		
2. Family history of p	2. Family history of premature ASCVD 4. High blood pressure		
5. Low HDL			

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.

Risk Group	Treatment Goals		Consider Drug T	herapy
	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)
Extreme Risk Group Category A	<50 (Optional goal	< 80 (Optional goal	>OR = 50	>OR = 80
	< OR = 30)	<or 60)<="" =="" td=""><td></td><td></td></or>		
Extreme Risk Group Category B	<or 30<="" =="" td=""><td><or 60<="" =="" td=""><td>> 30</td><td>>60</td></or></td></or>	<or 60<="" =="" td=""><td>> 30</td><td>>60</td></or>	> 30	>60
Very High Risk	<50	<80	>OR= 50	>OR= 80
High Risk	<70	<100	>OR= 70	>OR=100
Moderate Risk	<100	<130	>OR=100	>OR=130
Low Risk	<100	<130	>OR=130*	>OR=160

*After an adequate non-pharmacological intervention for at least 3 months.

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

LIVER FUNCTION PROFILE, SERUM

BILIRUBIN, TOTAL	0.72	Upto 1.2	mg/dL
BILIRUBIN, DIRECT METHOD : DIAZO COLORIMETRIC	0.26 High	Upto 0.2	mg/dL
BILIRUBIN, INDIRECT	0.46	0.00 - 1.00	mg/dL
	6.7	6.4 - 8.3	g/dL
ALBUMIN METHOD : BROMOCRESOL GREEN	4.8	3.5 - 5.2	g/dL

Dr.Miral Gajera Consultant Pathologist

Page 11 Of 19

View Report







PATIENT NAME : SMIT CHANDARANA	REF. DOCTOR :	SELF
CODE/NAME & ADDRESS : C000138364	ACCESSION NO : 0321WK000908	AGE/SEX : 30 Years Male
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	PATIENT ID : SMITM021292321	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 25/11/2023 09:37:22
NEW DELHI 110030	ABHA NO :	REPORTED :27/11/2023 16:15:10
8800465156		

Test Report Status <u>Final</u>	Results	Biological Reference Interva	al Units
GLOBULIN	1.9 Low	2.0 - 4.1	g/dL
ALBUMIN/GLOBULIN RATIO	2.5 High	1.0 - 2.0	RATIO
ASPARTATE AMINOTRANSFERASE(AST/SGOT) METHOD : IFCC WITHOUT PYRIDOXAL-5-PHOSPHATE	18	0 - 40	U/L
ALANINE AMINOTRANSFERASE (ALT/SGPT) METHOD : IFCC WITHOUT PYRIDOXAL-5-PHOSPHATE	25	0 - 41	U/L
ALKALINE PHOSPHATASE METHOD : COLORIMETRIC	57	40 - 129	U/L
GAMMA GLUTAMYL TRANSFERASE (GGT) METHOD : ENZYMATIC, COLORIMETRIC	50	8 - 61	U/L
LACTATE DEHYDROGENASE METHOD : UV ASSAY METHOD	174	135 - 225	U/L
BLOOD UREA NITROGEN (BUN), SERUM			
BLOOD UREA NITROGEN	11	6 - 20	mg/dL
CREATININE, SERUM			
CREATININE METHOD : JAFFE ALKALINE PICRATE	0.77	0.70 - 1.30	mg/dL
BUN/CREAT RATIO			
BUN/CREAT RATIO	14.29	5.0 - 15.0	
URIC ACID, SERUM			
URIC ACID	6.3	3.4 - 7.0	mg/dL
TOTAL PROTEIN, SERUM			
TOTAL PROTEIN	6.7	6.4 - 8.3	g/dL
METHOD : COLORIMETRIC			
ALBUMIN, SERUM			
ALBUMIN METHOD : BROMOCRESOL GREEN	4.8	3.5 - 5.2	g/dL
GLOBULIN			
GLOBULIN	1.9 Low	2.0 - 4.1	g/dL
ELECTROLYTES (NA/K/CL), SERUM			
SODIUM, SERUM	136.4	136- 145	mmol/L
POTASSIUM, SERUM	4.67	3.50- 5.10	mmol/L
CHLORIDE, SERUM	105.3	98 - 107	mmol/L
Interpretation(s)			

Dr.Miral Gajera Consultant Pathologist

Page 12 Of 19







PATIENT NAME : SMIT CHANDARANA	REF. DOCTOR : S	SELF
CODE/NAME & ADDRESS : C000138364	ACCESSION NO : 0321WK000908	AGE/SEX : 30 Years Male
	PATIENT ID : SMITM021292321	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 25/11/2023 09:37:22
NEW DELHI 110030	ABHA NO :	REPORTED :27/11/2023 16:15:10
8800465156		

Test Report Status Final Results

Biological Reference Interval Units

Sodium	Potassium	Chloride
Decreased in:CCF, cirrhosis,	Decreased in: Low potassium	Decreased in: Vomiting, diarrhea,
vomiting, diarrhea, excessive	intake, prolonged vomiting or diarrhea,	renal failure combined with salt
sweating, salt-losing	RTA types I and II,	deprivation, over-treatment with
nephropathy, adrenal insufficiency,	hyperaldosteronism, Cushing's	diuretics, chronic respiratory acidosis,
nephrotic syndrome, water	syndrome,osmotic diuresis (e.g.,	diabetic ketoacidosis, excessive
intoxication, SIADH. Drugs:	hyperglycemia), alkalosis, familial	sweating, SIADH, salt-losing
thiazides, diuretics, ACE inhibitors,	periodic paralysis,trauma	nephropathy, porphyria, expansion of
chlorpropamide, carbamazepine, anti	(transient).Drugs: Adrenergic agents,	extracellular fluid volume,
depressants (SSRI), antipsychotics.	diuretics.	adrenalinsufficiency,
		hyperaldosteronism, metabolic
		alkalosis. Drugs: chronic
		laxative,corticosteroids, diuretics.
Increased in: Dehydration	Increased in: Massive hemolysis,	Increased in: Renal failure, nephrotic
(excessivesweating, severe	severe tissue damage, rhabdomyolysis,	syndrome, RTA, dehydration,
vomiting or diarrhea), diabetes	acidosis, dehydration, renal failure,	overtreatment with
mellitus, diabetesinsipidus,	Addison's disease, RTA type IV,	saline,hyperparathyroidism, diabetes
hyperaldosteronism, inadequate	hyperkalemic familial periodic	insipidus, metabolic acidosis from
water intake. Drugs: steroids,	paralysis. Drugs: potassium salts,	diarrhea (Loss of HCO3-), respiratory
licorice, oral contraceptives.	potassium- sparing diuretics, NSAIDs,	alkalosis, hyperadrenocorticism.
	beta-blockers, ACE inhibitors, high-	Drugs: acetazolamide, androgens,
	dose trimethoprim-sulfamethoxazole.	hydrochlorothiazide, salicylates.
Interferences: Severe lipemia or	Interferences: Hemolysis of sample,	Interferences:Test is helpful in
hyperproteinemi, if sodium analysis	delayed separation of serum,	assessing normal and increased anion
involves a dilution step can cause	prolonged fist clenching during blood	gap metabolic acidosis and in
spurious results. The serum sodium	drawing, and prolonged tourniquet	distinguishing hypercalcemia due to
falls about 1.6 mEq/L for each 100	placement. Very high WBC/PLT counts	hyperparathyroidism (high serum
mg/dL increase in blood glucose.	may cause spurious. Plasma potassium	chloride) from that due to malignancy
	levels are normal.	(Normal serum chloride)

Interpretation(s) GLUCOSE FASTING,FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the urine.

Increased in: Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs: corticosteroids, phenytoin, estrogen, thiazides.

Decreased in : Pancreatic islet cell disease with increased insulin, insulinoma, adrenocortical insufficiency, hypopituitarism, diffuse liver disease malignancy(adrenocortical,stomach,fibrosarcoma),infant of a diabetic mother,enzyme deficiency diseases(e.g.galactosemia),Drugs-insulin,ethanol,propranolol

sulfonylureas,tolbutamide,and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin (HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glycaemics & Insulin treatment, Renal Glycaemic & Insulin response & sensitivity etc.

treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood.ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of

Dr.Miral Gajera **Consultant Pathologist**



Page 13 Of 19

View Report

View Details





PATIENT NAME : SMIT CHANDARANA	REF. DOCTOR : SELF		
	ACCESSION NO : 0321WK000908 PATIENT ID : SMITM021292321	AGE/SEX : 30 Years Male	
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030	CLIENT PATIENT ID: ABHA NO :	RECEIVED : 25/11/2023 09:37:22 REPORTED : 27/11/2023 16:15:10	
8800465156			
Test Report Status Final	Results Biological	Reference Interval Units	

hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen

in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease. GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc.

Total Protein also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease.Lower-than-normal levels may be due to: Agammaglobulinemia,Bleeding (hemorrhage),Burns,Glomerulonephritis,Liver disease, Malabsorption,Malnutrition,Nephrotic syndrome,Protein-losing enteropathy etc.

Albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by:Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc

BLODD UREA NITROGEN (BUN), SERUM-**Causes** of **Increased** levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

Causes of decreased level include Liver disease, SIADH.

 CREATININE, SERUM-Higher than normal level may be due to:
 Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia) Lower than normal level may be due to:• Myasthenia Gravis, Muscuophy

URIC ACID, SERUM-Causes of Increased levels: Dietary(High Protein Intake, Prolonged Fasting, Rapid weight loss), Gout, Lesch nyhan syndrome, Type 2 DM, Metabolic syndrome Causes of decreased levels-Low Zinc intake, OCP, Multiple Sclerosis

TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin.

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic

syndrome, Protein-losing enteropathy etc. ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. **Low blood albumin levels (hypoalbuminemia) can be caused by:** Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance,malnutrition and wasting etc.

Dr.Miral Gajera Consultant Pathologist





View Report

Page 14 Of 19

Vie<u>w Details</u>





PATIENT NAME : SMIT CHANDARANA	REF. DOCTOR : S	SELF
	ACCESSION NO : 0321WK000908	AGE/SEX : 30 Years Male
	PATIENT ID : SMITM021292321	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 25/11/2023 09:37:22
NEW DELHI 110030	ABHA NO :	REPORTED :27/11/2023 16:15:10
8800465156		

Test	Report	Status	<u>Final</u>
------	--------	--------	--------------

Biological Reference Interval Units

	AL PATH - URINALYSIS			
MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE				
PHYSICAL EXAMINATION, URINE				
COLOR	Yellow			
APPEARANCE	Clear			
CHEMICAL EXAMINATION, URINE				
PH	5.0	4.7 - 7.5		
METHOD : REFLECTANCE SPECTROPHOTOMETRY				
SPECIFIC GRAVITY METHOD : REFLECTANCE SPECTROPHOTOMETRY	<=1.005	1.003 - 1.035		
PROTEIN METHOD : REFLECTANCE SPECTROPHOTOMETRY	NOT DETECTED	NEGATIVE		
GLUCOSE METHOD : REFLECTANCE SPECTROPHOTOMETRY	NOT DETECTED	NEGATIVE		
KETONES METHOD : REFLECTANCE SPECTROPHOTOMETRY	NOT DETECTED	NOT DETECTED		
BLOOD METHOD : REFLECTANCE SPECTROPHOTOMETRY	NOT DETECTED	NEGATIVE		
BILIRUBIN METHOD : REFLECTANCE SPECTROPHOTOMETRY	NOT DETECTED	NOT DETECTED		
UROBILINOGEN METHOD : REFLECTANCE SPECTROPHOTOMETRY	NORMAL	NORMAL		
NITRITE METHOD : REFLECTANCE SPECTROPHOTOMETRY	NOT DETECTED	NOT DETECTED		
LEUKOCYTE ESTERASE METHOD : REFLECTANCE SPECTROPHOTOMETRY	NOT DETECTED	NOT DETECTED		
MICROSCOPIC EXAMINATION, URINE				
RED BLOOD CELLS METHOD : MICROSCOPIC EXAMINATION	NOT DETECTED	NOT DETECTED	/HPF	
PUS CELL (WBC'S) METHOD : MICROSCOPIC EXAMINATION	0-1	0-5	/HPF	
EPITHELIAL CELLS METHOD : MICROSCOPIC EXAMINATION	1-2	0-5	/HPF	
CASTS METHOD : MICROSCOPIC EXAMINATION	NOT DETECTED			

Dr.Miral Gajera Consultant Pathologist

Page 15 Of 19







PATIENT NAME : SMIT CHANDARANA	REF. DOCTOR : SELF	
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	ACCESSION NO : 0321WK000908 PATIENT ID : SMITM021292321 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :30 Years Male DRAWN : RECEIVED :25/11/2023 09:37:22 REPORTED :27/11/2023 16:15:10
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units

CRYSTALS	NOT DETECTED	
METHOD : MICROSCOPIC EXAMINATION		
BACTERIA	NOT DETECTED	NOT DETECTED
METHOD : MICROSCOPIC EXAMINATION		
YEAST	NOT DETECTED	NOT DETECTED
METHOD : MICROSCOPIC EXAMINATION		
REMARKS	MICROSCOPIC EXAMINATION OF URINE CARRIED OUT ON CENTRIFUGED URINARY SEDIMENT.	

Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions
Proteins	Inflammation or immune illnesses
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind of kidney impairment
Glucose	Diabetes or kidney disease
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst
Urobilinogen	Liver disease such as hepatitis or cirrhosis
Blood	Renal or genital disorders/trauma
Bilirubin	Liver disease
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary tract infection and glomerular diseases
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either acute or chronic, polycystic kidney disease, urolithiasis, contamination by genital secretions
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or bladder catheters for prolonged periods of time
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration, interaction with Bence-Jones protein
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal diseases
Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit (Averrhoa carambola) or its juice
Uric acid	arthritis

Dr.Miral Gajera Consultant Pathologist

Email : customercare.ahmedabad@agilus.in

PERFORMED AT : Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India Tel : 079-48912999,079-48913999,079-48914999 Page 16 Of 19

View Report







PATIENT NAME : SMIT CHANDARANA	REF. DOCTOR :	SELF
CODE/NAME & ADDRESS : C000138364	ACCESSION NO : 0321WK000908	AGE/SEX : 30 Years Male
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST	PATIENT ID : SMITM021292321	DRAWN :
DELHI	CLIENT PATIENT ID: ABHA NO :	RECEIVED : 25/11/2023 09:37:22 REPORTED : 27/11/2023 16:15:10
NEW DELHI 110030 8800465156		121 OKIED 27/11/2023 10.13.10
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units

Bacteria	Urinary infectionwhen present in significant numbers & with pus cells.
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis

Dr.Miral Gajera Consultant Pathologist

PERFORMED AT : Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India Tel : 079-48912999,079-48913999,079-48914999 Email : customercare.ahmedabad@agilus.in Page 17 Of 19



View Details View Report





PATIENT NAME : SMIT CHANDARANA	REF. DOCTOR : S	SELF
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	PATIENT ID : SMITM021292321 CLIENT PATIENT ID:	AGE/SEX :30 Years Male DRAWN : RECEIVED :25/11/2023 09:37:22 REPORTED :27/11/2023 16:15:10
Test Report Status Final	Results Biological	Reference Interval Units

Biological Reference Interval Units

SPECIALISED CHEMISTRY - HORMONE			
MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE			
THYROID PANEL, SERUM			
ТЗ	149.90	80.0 - 200.0	ng/dL
METHOD : ECLIA			
T4	10.11	5.10 - 14.10	µg/dL
METHOD : ECLIA			
TSH (ULTRASENSITIVE)	2.640	0.270 - 4.200	µIU/mL
METHOD : ECLIA			
Interpretation(c)			

Interpretation(s)

Triiodothyronine T3 , Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3.Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)
					Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid
					hormone replacement therapy (3) In cases of Autoimmune/Hashimoto
					thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical
					inflammation, drugs like amphetamines, Iodine containing drug and
					dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre
					(3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid
					hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4
					replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism
6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent
					treatment for Hyperthyroidism

Dr.Miral Gajera Consultant Pathologist



Page 18 Of 19

View Report

View Details





PATIENT NAME : SMIT CHANDARANA	REF. DOCTOR : SELF			
		AGE/SEX : 30 Years Male		
F-703, LADO SARAI, MEHRAULISOUTH WEST	1 STITTO21252521	DRAWN : RECEIVED : 25/11/2023 09:37:22		
NEW DELHI 110030 8800465156	ABHA NO :	REPORTED :27/11/2023 16:15:10		
	1	1		

Fest Report Status	Final
---------------------------	-------

Biological Reference Interval Units

8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies
REF: 1. TIETZ Fundamentals of Clinical chemistry 2. Guidlines of the American Thyroid association duriing pregnancy and Postpartum, 2011.					
NOTE: It is advisable to detect Free T3.FreeT4 along with TSH, instead of testing for albumin bound Total T3. Total T4.TSH is not					

affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

> **End Of Report** Please visit www.agilusdiagnostics.com for related Test Information for this accession

CONDITIONS OF LABORATORY TESTING & REPORTING

- It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
 All tests are performed and reported as per the turnaround time stated in the AGILUS Directory of Services.
 Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.
 A requested test might not be performed if:
 - i. Specimen received is insufficient or inappropriate
 - ii. Specimen quality is unsatisfactory
 - iii. Incorrect specimen type

iv. Discrepancy between identification on specimen container label and test requisition form

5. AGILUS Diagnostics confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.

6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.

7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.

8. Test results cannot be used for Medico legal purposes.

9. In case of queries please call customer care

(91115 91115) within 48 hours of the report.

Agilus Diagnostics Ltd

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062

Dr.Miral Gajera Consultant Pathologist



Page 19 Of 19





